Circulation Research

Humacyte Second Quarter 2022 Financial Results and Business Update

Retrieved on: 
Friday, August 12, 2022
JAMA Surgery, HAV, University Hospital Heidelberg, Risk, Amputation, GLOBE, Investment, CABG, Conference call, Hospital, Trauma, Femoral artery, Tissue, Board, Research, Pharmacy, Income, Patient, Cell, HUMA, Company, Acquisition, BCVS, Circulation Research, Vibration, University of Southern California, Chronic kidney disease, Lists of people executed in the United States, Disease, Infection, Publication, Maintenance, KOL, Board of directors, Denver Health Medical Center, CPRA, Insurance, University, Nasdaq, University of Bonn, AstraZeneca, Time, Conference, Duke University, Dentistry, Management, Pharmaceutical industry, Medical device, Lithium

-- Conference call and live webcast at 8:00 a.m. ET today –

Key Points: 
  • ET today
    DURHAM, N.C., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues, complex tissue systems, and organs at commercial scale, today announced financial results for the second quarter ended June 30, 2022, and highlighted recent corporate accomplishments.
  • Early in the second quarter, Humacyte launched an initiative to provide its HAVs to hospitals in Ukraine for the treatment of wounded civilians and soldiers with vascular trauma injuries.
  • Revenue was $1.3 million for the second quarter of 2022, compared to $0.7 million for the second quarter of 2021, and was $1.5 million for the six months ended June 30, 2022, compared to $0.8 million for the six months ended June 30, 2021.
  • Other net income was $55.4 million for the second quarter of 2022, compared to $2.1 million for the second quarter of 2021, and was $57.3 million for the six months ended June 30, 2022, compared to $1.5 million for the six months ended June 30, 2021.

Humacyte Preclinical Data on Small-Diameter Human Acellular Vessel™ (HAV™) in Coronary Artery Bypass Grafting (CABG) Presented at American Heart Association Meeting

Retrieved on: 
Tuesday, July 26, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Sale, Infection, GLOBE, American Heart, Injury, Saphenous, Fast track (FDA), Research, Food, Tissue, BCVS, Diabetes, Forward-looking statement, SEC, AV, Vibration, Partnership, Ligation, Histology, HAV, Intention, Risk, Safety, COVID-19, Duke University, Angiography, Technology, FDA, Company, HUMA, Patient, Heart, Nasdaq, Pain, Fresenius Medical Care, Annual report, Terminology, Risk-based testing, CABG, Animal, Moyamoya disease, Circulation Research, Medicine, Pharmaceutical industry, Medical imaging, Defense

DURHAM, N.C., July 25, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced results evaluating the use of the small-diameter (3.5mm) Human Acellular Vessel (HAV) for coronary artery bypass grafting (CABG) in a non-human primate model. The HAV was observed to maintain structural integrity and patency for up to six months post-implantation and showed evidence of robust host cell repopulation and remodeling. The results were presented by Adam Williams, M.D., cardiothoracic surgeon, Duke University, at the American Heart Association Basic Cardiovascular Sciences Scientific Sessions (BCVS) 2022 in Chicago, IL on July 25, 2022, and will be published in the September issue of Circulation Research.

Key Points: 
  • CABG is one of the most common surgical procedures, and we are often limited by our ability to find suitable conduit.
  • In the preclinical study, CABG surgery was performed using small-diameter HAVs implanted into seven non-immunosuppressed, non-human primates following ligation of the proximal coronary artery.
  • Human Acellular Vessels (HAV) are investigational engineered off-the-shelf replacement vessels initially being developed for vascular repair, reconstruction and replacement.
  • Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications.